Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 26, 2026
Comparing NWBI and WABC: Regional Banks Posting +25% to +30% YTD Returns

Comparing NWBI and WABC: Regional Banks Posting +25% to +30% YTD Returns

Key Takeaways

  • NWBI and WABC operate as regional bank holding companies but in distinct regions with contrasting growth approaches.
  • Northwest Bancshares focuses on acquisitions and commercial lending expansion, whereas Westamerica Bancorporation maintains a conservative, efficiency-oriented model in California.
  • Both stocks have generated strong year-to-date gains in the 25% to 30% range, outperforming the broader market.
  • NWBI provides a notably higher dividend yield, while WABC demonstrates stronger profitability and return on equity.
  • With closely matched relative performance, the key distinctions lie in risk profiles, potential catalysts, and geographic positioning.

Why Compare These Two Regional Banks?

Investors seeking regional bank exposure frequently evaluate names that operate in the same sector yet differ in business models, locations, and strategic directions. NWBI (Northwest Bancshares) and WABC (Westamerica Bancorporation) present a clear case for comparison. Both have established histories as community and regional lenders, but they occupy different positions along the growth and profitability spectrum. This matters for income investors focused on dividend yields as well as those monitoring relative performance and momentum in financials. I also checked this using Tickeron’s AI Screener to see how the stocks stack up against industry peers.

A Closer Look at NWBI

NWBI serves as the holding company for Northwest Bank, a state-chartered savings bank with operations across Pennsylvania, New York, Ohio, and Indiana. Growth initiatives, including the integration of the Penns Woods Bancorp acquisition and plans for a new headquarters in Dublin, Ohio, have shaped recent activity. Record quarterly net income has been supported by commercial lending and net interest margin expansion. Over the past year, NWBI has delivered a total return of roughly 24% to 29%, with year-to-date gains near the upper end of that range. The stock has moved within a 52-week band of about $11.25 to $16.16. A dividend yield in the low-to-mid 5% range and a relatively low beta add to its appeal for some investors, though credit quality in commercial real estate and execution of expansion plans remain areas to monitor.

A Closer Look at WABC

WABC holds Westamerica Bank, which offers deposit, lending, and related services primarily in Northern and Central California. Established in 1884 and based in San Rafael, the firm follows a conservative, efficiency-driven approach that has produced high profit margins and solid returns on assets compared with many peers. Recently, WABC has traded near the top of its 52-week range of roughly $44.93 to $63.61. Year-to-date returns stand around 30%, with one-year total returns in the mid-to-high 20% range. The stock shows an even lower beta than NWBI, reflecting reduced volatility. Its dividend yield sits near 3.2%, yet return on equity stands out as stronger. Concentration in California and a more limited acquisition strategy are factors to consider.

Strategic Differences and Valuation

The main distinction lies in strategic posture. NWBI pursues expansion through acquisitions and commercial loan growth, which brings potential catalysts alongside execution and credit risks. WABC, in contrast, emphasizes internal efficiency and balance-sheet conservatism, supporting higher profitability margins and returns on assets. On valuation and income, NWBI offers a higher dividend yield attractive to income investors, though it trades at a somewhat elevated price-to-earnings multiple. WABC features a lower earnings multiple and superior profitability metrics, offset by a more modest yield. Geographically, NWBI spans four Midwest and Mid-Atlantic states, while WABC remains focused on California. Both exhibit below-market betas, with WABC showing the lower volatility profile.

What the AI Models Suggest

From what I see, observable factors such as trend consistency, relative positioning, and stability point to different considerations for each stock depending on objectives. WABC’s steadier uptrend, higher profitability, and lower beta may appeal more for momentum and lower-volatility strategies. NWBI holds advantages in dividend income and growth catalysts. On balance, an AI-oriented view toward trend consistency and risk-adjusted stability leans somewhat toward WABC, while recognizing NWBI’s edge on income and expansion opportunities. This remains a probabilistic assessment of positioning rather than a firm forecast.

Exploring AI-Powered Strategies

I often review Tickeron’s Trending AI Robots to identify automated strategies that align with prevailing market conditions. The page highlights top-performing bots from a large library, each with distinct styles, timeframes, and performance data, updated to reflect current environments. This can add useful context when comparing stocks such as NWBI and WABC.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NWBI, WABC

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


NWBI sees its Stochastic Oscillator ascending out of oversold territory

On October 02, 2026, the Stochastic Oscillator for NWBI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 62 instances where the indicator left the oversold zone. In 39 of the 62 cases the stock moved higher in the following days. This puts the odds of a move higher at over 63%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +2.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where NWBI advanced for three days, in 156 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.

NWBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NWBI as a result. In 50 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.

The Moving Average Convergence Divergence Histogram (MACD) for NWBI turned negative on September 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 24 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 51%.

NWBI moved below its 50-day moving average on September 21, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NWBI crossed bearishly below the 50-day moving average on September 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NWBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.

The Aroon Indicator for NWBI entered a downward trend on September 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.149) is normal, around the industry mean (1.321). P/E Ratio (14.680) is within average values for comparable stocks, (24.015). Projected Growth (PEG Ratio) (0.090) is also within normal values, averaging (1.186). NWBI has a moderately high Dividend Yield (0.053) as compared to the industry average of (0.030). P/S Ratio (3.193) is also within normal values, averaging (3.747).

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 33 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 57, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. NWBI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

Notable companies

The most notable companies in this group are Itau Unibanco Banco Holding SA (NYSE:ITUB), US Bancorp (NYSE:USB), PNC Financial Services Group (NYSE:PNC), Deutsche Bank Aktiengesellschaft (NYSE:DB), Banco Bradesco SA (NYSE:BBD), Huntington Bancshares (NASDAQ:HBAN), Regions Financial Corp (NYSE:RF), KeyCorp (NYSE:KEY).

Industry description

Regional banks have a smaller reach than major banks, and cater mostly to one region of a country, such as a state or within a group of states. They offer services often similar – albeit with some limitations/smaller scale – compared to major banks. Taking deposits, making loans, mortgages, leases, credit cards , fund management, insurance and investment banking. SunTrust Banks, State Street Corp., M&T Bank Corp. are some examples of U.S. regional banks.

Market Cap

The average market capitalization across the Regional Banks Industry is 6.12B. The market cap for tickers in the group ranges from 22.65 to 173.74B. DBSDF holds the highest valuation in this group at 173.74B. The lowest valued company is VLYPP at 22.65.

High and low price notable news

The average weekly price growth across all stocks in the Regional Banks Industry was 1%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 6%. INTR experienced the highest price growth at 30%, while SHFS experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Regional Banks Industry was 61%. For the same stocks of the Industry, the average monthly volume growth was 173% and the average quarterly volume growth was 48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 50
Price Growth Rating: 49
SMR Rating: 38
Profit Risk Rating: 57
Seasonality Score: 53 (-100 ... +100)
View a ticker or compare two or three
NWBI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a savings bank

Industry RegionalBanks

Industry
Savings Banks
Address
3 Easton Oval
Phone
+1 814 726-2140
Employees
2233
Web
https://www.northwest.bank
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.